Replies to post #184994 on Biotech Values

[DewDiligence]

One can be sure that JnJ's legal department will be working overtime starting today.

Actually, I doubt that. JNJ is no longer a serious player in the HCV market because they’ve developed only a single drug (simeprevir) rather than a full HCV regimen. Thus, ESRX could successfully argue that JNJ wasn’t going to be able to maintain any meaningful market share regardless of ESRX’s actions.

At this point, the “collusion” issue (as posited by ‘bladerunner’) affects only ABBV and GILD.